[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.140.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1996

Postnatal Variations of Growth Hormone Bioactivity and of Growth Hormone-Dependent Factors

Author Affiliations

From the Department of Pediatrics, University of Pavia, Pavia, Italy (Drs Bozzola, Tettoni, Locatelli, Zecca, and Severi); the Department of Pediatrics, Bolzano, Bolzano, Italy (Dr Radetti); the Neonatal Intensive Care Unit (Dr Belloni) and Department of Clinical Chemistry (Dr Autelli), IRCCS Policlinico San Matteo, Pavia; and the Department of Pediatrics, University of Verona, Verona, Italy (Drs Valentini and Tatò).

Arch Pediatr Adolesc Med. 1996;150(10):1068-1071. doi:10.1001/archpedi.1996.02170350070012
Abstract

Objective:  To evaluate whether the low insulinlike growth factor I (IGF-I) levels that are observed in the neonate depend on the biological inactivity of the molecular forms of growth hormone (GH) or on the immaturity of the hepatic GH receptors during the early postnatal period.

Materials and Methods:  Serum samples were collected from 60 normal full-term neonates on day 5 and at 1 and 4 months of age to evaluate the GH concentrations by using both an immunofluorometric assay and Nb2 cell bioassay, as well as the GH-binding protein, IGF-I, and IGF–binding protein 3 values by radioimmunoassay.

Results:  Five-day-old neonates showed significantly higher (P<.001) mean±SEM GH levels that were measured by using the immunofluorometric assay (27.22±1.62 μg/L) and Nb2 cell bioassay (3.56±0.14 U/mL) compared with those levels in 11 prepubertal children who were studied as control subjects (1.26±0.28 μg/L and 0.74±0.08 U/mL, respectively). At 1 and 4 months of age, GH values that were measured by using both the immunofluorometric assay (9.15±0.89 and 2.58±0.32 μg/L, respectively) and Nb2 cell bioassay (2.52±0.11 and 1.71±0.15 U/mL, respectively) were decreased significantly (P<.001). In 5-day-old neonates, we observed significantly lower (P<.001) serum GH-bindingprotein (9.73%±0.42%), IGF-I (67.63±5.20 ng/mL), and IGF-binding protein 3 (1.46±0.17 mg/L) concentrations compared with those in the prepubertal children (30.74%±2.01%, 210±25 ng/mL, and 3.08±0.22 mg/L, respectively). At 1 month of age, serum GH-binding protein (16.00%±0.70%) and IGF-binding protein 3 (2.96±0.30 mg/L) values were increased significantly (P<.001), while IGF-I levels (72.55±7.6 ng/mL, P=.09) were not increased. Serum IGF-I values were increased significantly (P<.005) at 4 months of age (97.94±9.68 ng/mL).

Conclusion:  The interaction of bioactive molecular forms of GH with the increased hepatic GH receptors induces the rise in postnatal IGF-I levels in early infancy.Arch Pediatr Adolesc Med. 1996;150:1068-1071

×